View All Documents & Correspondence
Novel Therapeutic Composition For Dermatitis
Abstract: The present invention relates to a composition comprising of steroid and bioenhancer for treating various skin disorders like dermatitis, eczema, psoriasis, etc wherein bioenhancer enhances bioavailability of the steroid by enabling significant improvement in skin penetration of steroid, resulting in high therapeutic efficacy of the composition as well as reducing the side effects and duration of therapy.
Notices, Deadlines & Correspondence
Patent Information
Applicants
CURATIO HEALTHCARE PVT LTD
Inventors
1. NARASIMHAN JAY KAUSHIK
Specification
DESC:As attached ,CLAIMS:1. A therapeutic composition for chronic skin diseases comprising a steroid agent as an active ingredient and a bioenhancerdiffused in hydrogel base to enhance the bioavailability of the said steroid thereby increasing the therapeutic efficacy of the said composition and deeply hydrate the affected skin which ensures reductionin the duration of the therapy with minimal side effects.
2. The therapeutic composition for chronic skin diseases according to claim 1, wherein the steroid agent is Corticosteroids and its pharmaceutically acceptable ester thereof in any chiral form or mixture.
3. The therapeutic composition for chronic skin diseases according to claim 1, wherein the bioenhancer is Tetrahydropiperine, methylsulfonylmethane (MSM), curcumin, glycyrrhizin or allicin thereof.
4. The therapeutic composition for chronic skin diseases according to claim 1, wherein the said composition is selected from the group consisting of creams, gel, lotion or ointment.
5. The therapeutic composition for chronic skin diseases according to claim 1 and claim 2, wherein the concentration of steroid is about 0.01% w/w and 5%w/w.
6. The therapeutic composition for chronic skin diseases according to claim 1 and claim 3, wherein the concentration of bioenhancer is about 0.1%w/w and 10%w/w.
7. The therapeutic composition for chronic skin diseases according to claim 1, wherein the said composition is administered topically.
8. The therapeutic composition for chronic skin diseases according to claim 1 to 6, wherein the chronic skin disease is a disease selected from the group consisting of dermatitis, eczema, psoriasis, urticaria and melasma.
9. The therapeutic composition for chronic skin diseases according to claim 1, wherein the whole of the composition is stable for eighteen months when the composition is subjected to stability studies.
10. The therapeutic composition for chronic skin diseases according to claim 1, wherein the whole of the composition could reduce the severity of the disease within 2 weeks of use when the composition is subjected to clinical studies.
Documents
Orders
| Section | Controller | Decision Date |
|---|---|---|
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 2148-CHE-2012 POWER OF ATTORNEY 29-05-2012.pdf | 2012-05-29 |
| 1 | 2148-CHE-2012-US(14)-HearingNotice-(HearingDate-14-09-2020).pdf | 2020-08-11 |
| 2 | 2148-CHE-2012-CLAIMS [20-06-2018(online)].pdf | 2018-06-20 |
| 2 | 2148-CHE-2012 FORM-2 29-05-2012.pdf | 2012-05-29 |
| 3 | 2148-CHE-2012-FER_SER_REPLY [20-06-2018(online)].pdf | 2018-06-20 |
| 3 | 2148-CHE-2012 FORM-1 29-05-2012.pdf | 2012-05-29 |
| 4 | 2148-CHE-2012 DESCRIPTION (PROVISIONAL) 29-05-2012.pdf | 2012-05-29 |
| 4 | 2148-CHE-2012-OTHERS [20-06-2018(online)].pdf | 2018-06-20 |
| 5 | 2148-CHE-2012-FER.pdf | 2017-12-20 |
| 5 | 2148-CHE-2012 CORRESPONDENCE OTHERS 29-05-2012.pdf | 2012-05-29 |
| 6 | Form 5.pdf | 2013-05-31 |
| 6 | Complete Specification.pdf | 2013-06-17 |
| 7 | 2148-CHE-2012 FORM-3 31-05-2013.pdf | 2013-05-31 |
| 7 | 2148-CHE-2012 CORRESPONDENE OTHERS 31-05-2013.pdf | 2013-05-31 |
| 8 | 2148-CHE-2012 FORM-3 31-05-2013.pdf | 2013-05-31 |
| 8 | 2148-CHE-2012 CORRESPONDENE OTHERS 31-05-2013.pdf | 2013-05-31 |
| 9 | Form 5.pdf | 2013-05-31 |
| 9 | Complete Specification.pdf | 2013-06-17 |
| 10 | 2148-CHE-2012 CORRESPONDENCE OTHERS 29-05-2012.pdf | 2012-05-29 |
| 10 | 2148-CHE-2012-FER.pdf | 2017-12-20 |
| 11 | 2148-CHE-2012 DESCRIPTION (PROVISIONAL) 29-05-2012.pdf | 2012-05-29 |
| 11 | 2148-CHE-2012-OTHERS [20-06-2018(online)].pdf | 2018-06-20 |
| 12 | 2148-CHE-2012-FER_SER_REPLY [20-06-2018(online)].pdf | 2018-06-20 |
| 12 | 2148-CHE-2012 FORM-1 29-05-2012.pdf | 2012-05-29 |
| 13 | 2148-CHE-2012-CLAIMS [20-06-2018(online)].pdf | 2018-06-20 |
| 13 | 2148-CHE-2012 FORM-2 29-05-2012.pdf | 2012-05-29 |
| 14 | 2148-CHE-2012-US(14)-HearingNotice-(HearingDate-14-09-2020).pdf | 2020-08-11 |
| 14 | 2148-CHE-2012 POWER OF ATTORNEY 29-05-2012.pdf | 2012-05-29 |
Search Strategy
| 1 | 2148_19-12-2017.pdf |